Galapagos NV ADR (GLPG) - Total Assets
Based on the latest financial reports, Galapagos NV ADR (GLPG) holds total assets worth $3.41 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See GLPG net assets for net asset value and shareholders' equity analysis.
Galapagos NV ADR - Total Assets Trend (2004–2025)
This chart illustrates how Galapagos NV ADR's total assets have evolved over time, based on quarterly financial data.
Galapagos NV ADR - Asset Composition Analysis
Current Asset Composition (December 2025)
Galapagos NV ADR's total assets of $3.41 Billion consist of 90.4% current assets and 9.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.6% |
| Accounts Receivable | $53.20 Million | 1.6% |
| Inventory | $22.49 Million | 0.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $847.64K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Galapagos NV ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Galapagos NV ADR (GLPG) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Galapagos NV ADR's current assets represent 90.4% of total assets in 2025, an increase from 80.3% in 2004.
- Cash Position: Cash and equivalents constituted 2.6% of total assets in 2025, down from 65.8% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 1.6% of total assets.
Galapagos NV ADR Competitors by Total Assets
Key competitors of Galapagos NV ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Galapagos NV ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 20.15 | 9.97 | 8.77 |
| Quick Ratio | 20.00 | 9.81 | 8.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.93 Billion | $3.00 Billion | $4.71 Billion |
Galapagos NV ADR - Advanced Valuation Insights
This section examines the relationship between Galapagos NV ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.51 |
| Latest Market Cap to Assets Ratio | 0.56 |
| Asset Growth Rate (YoY) | -17.7% |
| Total Assets | $3.41 Billion |
| Market Capitalization | $1.89 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Galapagos NV ADR's assets below their book value (0.56x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Galapagos NV ADR's assets decreased by 17.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Galapagos NV ADR (2004–2025)
The table below shows the annual total assets of Galapagos NV ADR from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.41 Billion | -17.67% |
| 2024-12-31 | $4.14 Billion | -5.09% |
| 2023-12-31 | $4.36 Billion | -7.96% |
| 2022-12-31 | $4.73 Billion | -8.83% |
| 2021-12-31 | $5.19 Billion | -9.17% |
| 2020-12-31 | $5.72 Billion | -5.78% |
| 2019-12-31 | $6.07 Billion | +321.58% |
| 2018-12-31 | $1.44 Billion | +11.91% |
| 2017-12-31 | $1.29 Billion | +18.73% |
| 2016-12-31 | $1.08 Billion | +144.81% |
| 2015-12-31 | $442.51 Million | +63.61% |
| 2014-12-31 | $270.47 Million | -5.88% |
| 2013-12-31 | $287.37 Million | +22.12% |
| 2012-12-31 | $235.33 Million | +46.12% |
| 2011-12-31 | $161.06 Million | -16.97% |
| 2010-12-31 | $193.96 Million | +34.97% |
| 2009-12-31 | $143.71 Million | +20.94% |
| 2008-12-31 | $118.82 Million | -20.10% |
| 2007-12-31 | $148.72 Million | -11.29% |
| 2006-12-31 | $167.65 Million | +105.54% |
| 2005-12-31 | $81.56 Million | +422.40% |
| 2004-12-31 | $15.61 Million | -- |
About Galapagos NV ADR
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more